Last reviewed · How we verify
NCT06265285
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Phase 2 trial testing Home Health Encounter in Advanced Esophageal Squamous Cell Carcinoma in 50 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Mayo Clinic |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 30 April 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Home Health Encounter
- Nivolumab (nivolumab) — full drug profile →
- Patient Monitoring
- Questionnaire Administration
Conditions studied
- Advanced Esophageal Squamous Cell Carcinoma — all drugs for Advanced Esophageal Squamous Cell Carcinoma →
- Advanced Renal Cell Carcinoma — all drugs for Advanced Renal Cell Carcinoma →
- Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 — all drugs for Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 →
- Clinical Stage IIB Cutaneous Melanoma AJCC v8 — all drugs for Clinical Stage IIB Cutaneous Melanoma AJCC v8 →
Sponsor
Mayo Clinic
Who can join
18 and older, any sex, with Advanced Esophageal Squamous Cell Carcinoma or Advanced Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends and familiar surroundings for many hours per day. This separation adds to the physical, emotional, social, and financial burden for patients and their families. Traveling to and from medical facilities costs time, money, and effort and can be a disadvantage to patients living in rural areas, those with low incomes or poor access to transport. Studies have shown that cancer patients often feel more comfortable and secure being cared for in their own home environments. SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve the quality of life in cancer patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer.
Grobler L, O'Connor D, Rischin D, Putrik P, et al · · 2025 · cited 2× · PMID 40260850 · DOI 10.1002/14651858.cd014861.pub2
Verify or expand the search:
- PubMed search for NCT06265285
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Home Health Encounter
Trials testing the same drug.
- NCT06704191 — In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial · Phase 1, PHASE2 · recruiting
- NCT05969860 — At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer · Phase 2 · recruiting
Other recruiting trials for Advanced Esophageal Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT06489197 — AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients · Phase 2 · recruiting
- NCT06512428 — A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma · Phase 2 · recruiting
- NCT05214222 — Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma · Phase 2 · recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
- NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06265285 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
- Last refreshed: 4 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06265285.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing